ASX dipped as Wall Street rallies on Fed-cut bets. But telcos, storage and gas names keep the market from sinking further.

Norm Seckold chaired Minerals Exploration is confident it can play a leading role in a modern day New Zealand gold rush.

Cell therapy oncology drug developers Imugene and Chimeric Therapeutics have won FDA support – albeit in different ways.

Guy Le Page looks at Boab Metals and the short runway to silver and base metals production from its Sorby Hills project in WA ...

Metals X has flagged its interest in boosting tin production as global supply tightens and demand from the semiconductor ...

Gold is the market leader right now, but unloved energy stocks could provide a 'natural hedge' if oil bounces off its lows.

With gold prices forecast to continue their strong run into the new year, Bubalus (ASX:BUS) has fired up a reverse ...

The ASX 200 was caught between a commodity rally and a rate hike squeeze this week, closing out trade unchanged for the ...

Pre-Christmas retail promotions such as Black Friday show consumers will spend – but only on certain items and almost always ...

Wildcat Resources cleared a major hurdle for the Tabba Tabba lithium project to little fanfare. But Barry FitzGerald is ...

Will gold prices continue to rip in 2026? The World Gold Council sees the case for more outsized gains if we wind up in a ...

Mining giants have fronted investors ahead of Christmas, with Glencore eyeing major copper growth and Rio trying to prove its ...